The Targeted Pulse: New Trial Evaluating Iadademstat/Azacitidine in MDS and Positive Trends in HNSCC
Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.
If you are worried about using this medicine, speak to your doctor or pharmacist. Azacitidine-Teva contains the active ingredient azacitidine. Azacitidine-Teva is used to treat myelodysplastic ...
For information, the company have announced that the STIMULUS program for Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes has been terminated and therefore they will no ...
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 ...
Citing Phase 1 data the company announced, Citi analyst Yigal Nochomovitz noted that SL-172154 with chemotherapy azacitidine ...
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results